Results 91 to 100 of about 3,073 (139)

The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records. [PDF]

Int J Clin Pharm
Kang MJ, Lee HK, Ko M, Jang HY, Kim IW, Oh JM.   +5 more
europepmc   +1 more source

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. [PDF]

BMC Pharmacol Toxicol
Ramalingam PS, Hussain MS, Chellasamy G, Elangovan S, Sharma D, T P, Mishra RAK, Kodiveri Muthukaliannan G, Hussain T, Alrokayan S, Balakrishnan P, Mekala JR, Arumugam S.   +12 more
europepmc   +1 more source

Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial. [PDF]

BMC Med
Barchetta I, Filardi T, Dule S, Cimini FA, Sentinelli F, Romagnoli E, Passarella G, Bleve E, Oldani A, Venditti V, Anastasi E, Gandini O, Napoli N, Nicolucci A, Lenzi A, Baroni MG, Morano S, Cavallo MG, SlowDOWN Study Network.   +18 more
europepmc   +1 more source

GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes. [PDF]

PLoS One
Zaveri K, Kulkarni G, Nair R, Shanmugan G, Dharmadhikari SA, Makkar RPS, Jalgaonkar R, Chatterjee BD, Korukonda K, GLIMSI Investigator(s) Study Panel.   +9 more
europepmc   +1 more source

The mechanism study of targeting DPP4 in regulating ferroptosis and its influence on endometrial receptivity in PCOS. [PDF]

Biol Sex Differ
Zhang J, Wang R, Tian X, Ding N, He Y, Wang K, Tao C, Cai J, Jian Q, Wang F.   +9 more
europepmc   +1 more source

Dual PTP1B/DPP4 Inhibitory Potential of <i>Agathosma betulina</i>, <i>Cymbopogon citratus</i>, and <i>Artemisia afra</i>: Structure-Based Modeling of Phytochemical Leads and Essential Oil Bioassays. [PDF]

Comput Struct Biotechnol J
Adedirin O, Sabiu S.
europepmc   +1 more source

Probing the mechanisms of flavonoids in corn silk for treating type 2 diabetes by in Silico and in vitro experiments. [PDF]

Sci Rep
Liu X, Wu H.
europepmc   +1 more source

Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). [PDF]

Diabetes Care
Gonzalez JS, Wen H, Butera NM, Uschner D, Krause-Steinrauf H, Gramzinski MR, Wexler DJ, Petrovitch H, Hoogendoorn CJ, Crespo-Ramos G, Presley C, Fattaleh B, Lagari V, Walker EA, Cherrington AL, GRADE Research Group*.   +15 more
europepmc   +1 more source

MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Santos AS, Bando SY, Correa Giannella MLC, da Silva MER.   +3 more
europepmc   +1 more source

Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study. [PDF]

Sci Rep
Shalaby YM, Al-Zohily B, Sudhadev M, Nemmar A, Al-Salam S, Akawi N.   +5 more
europepmc   +1 more source